SLC39A1 and prostate cancer: One must begin with the recognition of two requirements for the efficacious employment of zinc against prostate cancer: 1) the bioavailability of sufficient zinc (i.e. the interstitial fluid zinc) for uptake by the prostate cells; and 2) the availability of a cellular zinc uptake process (e.g. ZIP1).